GUSHENGTANG (02273): Full-time Reconstruction of the Commercial Foundation, A New Era of Value Reassessment Begins

On August 28, GUSHENGTANG (02273) released its interim results for 2026, visually demonstrating its accelerated profit quality release and firm commitment to shareholder returns in the capital market. During the reporting period, the company achieved revenue of 1.65 billion RMB, a year-on-year increase of 10.6%; net profit reached 220 million RMB, a significant jump of 44.2% year-on-year, showcasing strong profit elasticity. Supported by ample cash flow, the company intends to distribute an interim dividend of 210 million RMB, coupled with cash reserves of 1.19 billion RMB, which establishes a solid financial safety cushion. However, behind this impressive financial report lies a structural transformation that warrants a renewed examination by the market: in the first half of the year, the proportion of full-time doctors among newly added doctors surpassed 40%, with the performance contribution of new doctors increasing by 50% year-on-year. This set of data signifies that GUSHENGTANG is leveraging a full-time strategy to fundamentally reconstruct its business foundationtransforming doctor resources from relatively loose external cooperation into a tighter endogenous growth engine. This proactive strategic upgrade positions the company precisely within the policy windfall of the "14th Five-Year Plan" for graded diagnosis and treatment, and, by continuing to enhance talent density, it is transforming organizational capability into valuation premiums, initiating a new cycle of profitability release and dual-driven value reassessment for shareholder returns. The proportion of new in-house doctors exceeds 40%, reconstructing the business foundation through a full-time paradigm GUSHENGTANG's 2026 interim report shows that the company has moved beyond the phase of relying on new store expansions for scale accumulation, and the foundation for endogenous growth is becoming increasingly solid, with same-store visitor growth reaching 12.9%. The fundamental force supporting this endogenous foundation comes from the systematic restructuring of the company's core human resourcesthe doctor team, whose ability to implement a full-time talent strategy has been thoroughly verified by operational data. During the reporting period, the proportion of in-house doctors among newly added offline doctors exceeded 40.3% for the first time. The establishment of the in-house doctor system not only effectively addresses the industry pain points of service standardization and patient stickiness but also, through controllable diagnosis and treatment processes, unified medical quality, and closed-loop clinical data, achieves a qualitative change from enhancing operational efficiency to consolidating brand assets. The qualitative transformation of the talent structure has been directly translated into strong performance increments. During the reporting period, the performance of new doctors saw a 50% year-on-year increase compared to the previous period, indicating a further strengthening of medical acquisition capabilities. Furthermore, the performance growth rate of new doctors who have been employed for over a year reached an astonishing 103.7%. These two data points together form a complete commercial validation loop: the overall growth rate of 50% verifies the scalable replicability of the full-time system, while the mature growth rate of 103.7% indicates that once the adaptation phase is passed, the performance elasticity of the in-house model will be powerfully released. The efficient conversion mechanism confirms that GUSHENGTANG not only possesses the capacity to attract talent but also has a mature talent empowerment system that effectively transforms human capital into sustainable momentum for same-store growth. The results on the talent front are ultimately concentrated in the store front. During the reporting period, the number of patients visiting the company's offline outpatient clinics increased by 17.5% year-on-year, with as high as 12.9 percentage points contributed by same-store growth. The accelerated release of operational leverage in mature stores signifies that the single-store profit model has exhibited notable cyclical resilience, laying a solid foundation for sustained mid- to long-term improvement in profitability. In summary, this is not merely a simple adjustment of personnel structure, but a reconstruction of the underlying logic of the business model. In the context of a sustained favorable policy environment for Chinese medicine development, GUSHENGTANG is completing a value leap from a "chain model" to a "platform brand." While the industry remains embroiled in a stock game of multi-point practice, GUSHENGTANG has reshaped its business foundation with a full-time talent system, locking in the main driver of competition for the next phase in the Chinese medicine chain track. Policy dividends accurately position the grassroots sector, allowing the leader to fully enjoy the benefits of graded diagnosis and treatment If the construction of a full-time talent system is GUSHENGTANG's internal skill, then the states top-level design for grassroots medical care provides the most suitable stage for this skill to be displayed. The strategic value of GUSHENGTANG lies in its precise positioning within the wave of medical resource redistribution driven by national top-level design. In April 2026, the General Office of the State Council issued "Several Measures for Accelerating the Construction of a Graded Diagnosis and Treatment System," clearly extending expert team outpatient services to grassroots levels and implementing differentiated payment for medical insurance to provide institutional guarantees for the orderly transfer of outpatient flow from tertiary hospitals to grassroots communities. The "15th Five-Year Plan" for the revitalization and development of traditional Chinese medicine further quantifies the certainty of grassroots Chinese medicine: the total number of diagnoses and treatments in Chinese medicine is projected to rise from 20.2% in 2025 to 23% in 2030, representing a net increase of about 300 million visits; the proportion of grassroots Chinese medicine diagnoses and treatments is set to increase from 26.07% to 27%; and the number of practicing physicians in Chinese medicine per thousand people is expected to rise from 0.64 to 0.71. These three indicators tilt towards grassrootsthis expansion in demand clarifies the source of growth, while downward supply provides service support, and payment incentives connect patient decision-making. The three forces resonate with each other, transforming the grassroots Chinese medicine market from a policy-driven direction into a certain growth track with clear quantitative anchor points, and raising the industry ceiling systematically. Policy dividends have opened an influx of patients at the grassroots level, while the key to embracing this wave of traffic lies in the competitive landscape of the talent supply side. Traditional community health service centers have long faced the structural dilemma of "being unable to retain personnel." GUSHENGTANG has restructured this logic through market mechanisms, forming a systematic competitive advantage over grassroots medical institutions. In terms of expert resource density, the company has gathered eight masters of traditional Chinese medicine, dozens of nationally renowned traditional Chinese medicine doctors, and hundreds of scholars in TCM, forming an expert network that is difficult for private TCM institutions to replicate. This array of esteemed doctors not only builds a trust barrier on the patient side but also creates a sustained "siphon effect" on high-quality middle-aged and young doctors. Regarding promotion pathways, in the first half of 2026, 50 doctors completed level promotions, bringing the total number of promotions over the last three years to 141. In the context of scarce opportunities for promotion in grassroots public institutions, GUSHENGTANG provides a predictable growth path for doctors with a clear corporate-level system, resulting in a year-on-year increase of 42.6% in total in-house doctors to 1,208. In the academic growth system, 152 famous doctor inheritance studios provide practical platforms for learning from masters; the "GUSHENG Lecture Hall" has successfully held seven sessions, led by masters of traditional Chinese medicine, with over 20,000 participating physicians per session. This creates an organized loop of "famous doctors teachingclinical practiceacademic enhancement," converting individual experiences scattered in famous doctors' clinics into scalable organizational capabilities. It is this "attracting talent, retaining it, and facilitating rapid growth" talent supply system that allows GUSHENGTANG to attract high-quality doctors into the grassroots graded diagnosis and treatment system while guiding patients to "sink down." Looking ahead, GUSHENGTANG's growth potential is clear and quantifiable. The market size of traditional Chinese medicine services in China has grown from 768.3 billion RMB in 2021 to 1.03 trillion RMB in 2025, and it is expected to expand to 1.51 trillion RMB by 2030. The growth rate of grassroots outpatient services is projected to consistently outpace the overall market. Currently, GUSHENGTANG's outpatient volume accounts for less than 1% of the national traditional Chinese medicine outpatient volumein mature sectors, the market share of leading chain brands typically reaches 5%-10%. In a trillion-level market, a 1 percentage point increase in market share corresponds to an incremental revenue space of about 10 billion RMB. As brand momentum continues to strengthen and the in-house doctor system takes root, GUSHENGTANG is poised to lead the complete commercial loop from "acquiring traffic" to "retaining volume" and then to "monetizing value" amidst the increasing concentration in the grassroots TCM market. Transforming talent barriers into valuation premiums, three-dimensional logic reshapes the pricing center When strong endogenous growth and clear strategic positioning form a closed loop, the valuation logic in the capital market also undergoes a qualitative shift. The value of GUSHENGTANG's full-time talent system is ascending from operational efficiency levels to a reconstruction of valuation logic in the capital market. In the chain medical sector, the core of pricing for enterprises lies in the certainty of profitability and the replicability of same-store growth. GUSHENGTANG has achieved systematic breakthroughs in both dimensions by building a full-time doctor system, pushing the valuation system from a single pricing model based on "scale growth" to a three-dimensional pricing model of "growth + certainty + profit quality." Full-time models mean stronger service control. The in-house doctor system enables closed-loop management of diagnosis and treatment processes, medical quality, and clinical data. The member retention rate continues to rise, with member income now accounting for 46.8% of total income, and the number of physicians consuming as members growing by 28.7% year-on-year. The enhanced patient stickiness directly translates into increased follow-up rates and decreased customer acquisition costs. Higher follow-up rates bring about more stable gross marginsagainst the backdrop of a 3.9% year-on-year decline in overall customer unit prices due to an increase in the share of consumption-based services, the unit price for serious medical care has increased by 2.4%, while the follow-up rate has simultaneously risen by 0.5 percentage points, reflecting that the value of core medical services continues to solidify, and operational efficiency is steadily improving. The full-time doctor system forms the core support for the company's profitabilitystronger service control leads to higher follow-up rates and customer unit prices, driving the annualized return on equity (ROE) from 12.8% to 21.5%, an increase of 8.7 percentage points year-on-year. This value chain, in which talent density transforms into organizational effectiveness, and from organizational effectiveness into financial outcomes, forms a solid foundation for sustaining valuation premiums.